Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + albumin-bound paclitaxel + trastuzumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral (pyrotinib), Intravenous Infusion (albumin-bound Paclitaxel, Trastuzumab)
01
Overview
This is a combination regimen consisting of three agents: pyrotinib, albumin-bound paclitaxel, and trastuzumab. Pyrotinib is an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor that targets HER1, HER2, and HER4 receptors. Albumin-bound paclitaxel (nab-paclitaxel) is a microtubule inhibitor formulated with human albumin to improve solubility and reduce hypersensitivity reactions compared to conventional formulations. Trastuzumab is a monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting proliferation of cells overexpressing this protein. The combination has been investigated as neoadjuvant therapy for patients with HER2-positive breast cancer, aiming to enhance pathological complete response rates by dual targeting of the HER family alongside cytotoxic chemotherapy. Clinical studies have demonstrated significant efficacy and manageable safety in this setting[4][7].
- Brand names
- Herceptin (trastuzumab)Abraxane (albumin-bound paclitaxel)
- Other names
- nab-paclitaxel (for albumin-bound paclitaxel)
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pyrotinib + albumin-bound paclitaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + albumin-bound paclitaxel + trastuzumab.